Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights

On November 3, 2022 Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, reported financial results for the third quarter ending September 30, 2022, and recent program highlights (Press release, Magenta Therapeutics, NOV 3, 2022, View Source [SID1234622920]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are building momentum in the MGTA-117 clinical trial with new clinical results and are making progress across our pipeline, including our second targeted conditioning program CD45-ADC," said Jason Gardner, President and Chief Executive Officer of Magenta Therapeutics, Inc. "In the MGTA-117 Phase 1/2 clinical trial, we continue to enroll and generate clinical data in higher-dose cohorts. Our preclinical work has been particularly helpful in predicting our clinical experience in these early dose cohorts regarding MGTA-117 activity at different exposure levels and the overall tolerability profile. We look forward to presenting available clinical data at ASH (Free ASH Whitepaper) and using our data to support interactions with regulators as we plan to advance MGTA-117 to stem cell transplant-eligible patients and into gene therapy."

Program Highlights:
MGTA-117 Phase 1/2 Clinical Trial Progression and Data Disclosure Expectations
MGTA-117 is Magenta’s most advanced targeted conditioning product candidate designed to deplete target cells prior to a patient undergoing stem cell transplant or receiving an ex vivo gene therapy product. The program is currently enrolling patients with relapsed/refractory acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS), in a Phase 1/2 dose escalation clinical trial. MGTA-117 is an anti-CD117 antibody conjugated to an amanitin payload. CD117, also known as c-Kit receptor, is highly expressed on hematopoietic stem cells, progenitor cells, and leukemic cells.

Enrollment Progress. Magenta has completed enrollment in Cohort 1 and Cohort 2. In addition, Magenta has enrolled a sufficient number of patients to complete Cohort 3, provided that the patients complete their respective dose-limiting toxicity (DLT) observation periods. No serious adverse events have been deemed to be related to MGTA-117, and no dose-limiting toxicities have been observed to date. Our clinical experience has confirmed that patients with relapsed/refractory AML are at high risk for multiple disease complications, including susceptibility to infection, all of which can rapidly progress at any time leading to severe morbidity or mortality. All enrolled patients have contributed data to the clinical trial independent of the completion of the DLT period.
Proof-of-Mechanism. Available clinical data, including new data since the ASH (Free ASH Whitepaper) abstract submission in August 2022, support proof-of-mechanism for MGTA-117 due to evidence of its ability to bind CD117-expressing cells, deplete CD117-expressing cells, clear the body rapidly and be well-tolerated.
Regulatory Plans. Magenta has initiated requests for formal engagement with multiple regulatory authorities for the purpose of transitioning the clinical program into transplant-eligible AML and MDS patients. The pending regulatory interactions are expected to focus on MGTA-117’s clinical data relating to target binding, drug clearance and stability and tolerability across multiple dose levels. All available clinical data will be used to support these regulatory interactions, as well as the predictive preclinical modeling in non-human primates that has closely matched our clinical experience to date.
Gene Therapy. Magenta expects data from the Phase 1/2 trial to also inform clinical development planning and enable regulatory engagements for MGTA-117 as a potential monotherapy prior to patients undergoing autologous ex vivo gene therapy. Magenta has existing clinical collaborations with gene therapy companies and anticipates entering into additional collaborations as data progresses.
ASH Presentations. As disclosed separately, Magenta will present clinical and preclinical data at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in December 2022. The MGTA-117 clinical presentation will include data on pharmacokinetics, pharmacodynamic activity and the tolerability of MGTA-117. In light of the need to collect and finalize complete Cohort 3 data, Magenta currently anticipates presenting Cohort 1 and Cohort 2 clinical data at ASH (Free ASH Whitepaper). Any data not included in the ASH (Free ASH Whitepaper) presentation is anticipated to be available at a scientific conference in Q1 2023.
CD45-Antibody Drug Conjugate (ADC): Second Targeted Conditioning Program
Magenta’s CD45-ADC is designed to selectively target and deplete both stem cells and immune cells and is intended to replace the use of chemotherapy and radiation-based conditioning prior to stem cell transplant in patients with blood cancers and autoimmune diseases.

Magenta has completed a dose-ranging toxicology preclinical study successfully with no unexpected findings. The data inform dosing for a Good Laboratory Practices toxicology study intended to support a planned Investigational New Drug (IND) application.
Manufacturing and other IND-enabling activities are ongoing, and Magenta is preparing for regulatory interactions and clinical development activities.
Magenta expects to provide a further update on the CD45-ADC program in December 2022.
MGTA-145 Stem Cell Mobilization and Collection
Magenta is developing MGTA-145, in combination with plerixafor, to improve the process by which stem cells are released out of the bone marrow and into the bloodstream, known as stem cell mobilization. The mobilized cells are then collected and available for transplant. This is the first step for patients and is required for the majority of transplants and stem cell gene therapies.

Magenta, in partnership with bluebird bio, has initiated a Phase 2 clinical trial in sickle cell disease to evaluate the utility of MGTA-145, in combination with plerixafor, for the mobilization and collection of stem cells in patients with sickle cell disease. Mobilization and collection are difficult in sickle cell disease patients where granulocyte colony-stimulating factor (GCSF) cannot be used, and there is a clear unmet medical need.
Magenta anticipates generating initial data from this clinical trial in December 2022 followed by a more comprehensive data set in H1 2023.
Financial Results:
Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2022, were $128.3 million, compared to $176.9 million as of December 31, 2021. The September cash balance includes gross proceeds of $3.0 million from our "at-the-market" facility. Magenta anticipates that its cash, cash equivalents and marketable securities will be sufficient to fund its current operational plan into Q2 2024.

Research and Development Expenses: Research and development expenses were $11.2 million in the third quarter of 2022, compared to $10.8 million in the third quarter of 2021. The increase was driven primarily by higher preclinical and manufacturing costs to support our IND-enabling studies for CD45-ADC, offset by a decrease in clinical trial costs related to our mobilization program.

General and Administrative Expenses: General and administrative expenses were $6.1 million for the third quarter of 2022, compared with $7.5 million in the third quarter of 2021. The decrease was primarily due to a decrease in stock-based compensation.

Net Loss: Net loss was $16.1 million for the third quarter of 2022, compared to net loss of $17.4 million for the third quarter of 2021.

Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting

On November 3, 2022 Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, reported that it will make three presentations relating to its ongoing clinical trials at the 2022 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, to be held in New Orleans from December 10-13, 2022 and virtually (Press release, Magenta Therapeutics, NOV 3, 2022, View Source [SID1234622919]). In addition, an academic collaborator will present data from a preclinical program from Magenta’s research platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have made significant progress in the MGTA-117 Phase 1/2 clinical trial and look forward to presenting clinical evidence at ASH (Free ASH Whitepaper) that we believe supports proof-of-mechanism for MGTA-117. We are also very encouraged by the predictive value of our MGTA-117 preclinical modeling which has closely matched our pharmacokinetics and pharmacodynamics clinical experience in the early cohorts of the ongoing study. We expect these results will collectively inform the continued development of MGTA-117, our most advanced targeted antibody-drug conjugate, to enable more patients to benefit from stem cell transplant and gene therapies," said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics.

MGTA-117: Antibody Drug Conjugate (ADC) Targeted Conditioning
MGTA-117 is Magenta’s most advanced targeted conditioning product candidate designed to deplete target cells prior to a patient undergoing stem cell transplant or receiving an ex vivo gene therapy product. The program is currently enrolling patients with relapsed/refractory acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS), in a Phase 1/2 dose escalation clinical trial. MGTA-117 is an anti-CD117 antibody conjugated to an amanitin payload. CD117, also known as c-Kit receptor, is highly expressed on hematopoietic stem cells, progenitor cells, and leukemic cells.

Oral presentation of updated clinical data from ongoing Phase 1/2 dose escalation clinical trial
Title: MGTA-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study
Date: Monday, December 12, 2022, 3:30 pm CT
Abstract Summary: Magenta is conducting a multicenter, open-label, dose-escalation clinical trial of MGTA-117 in relapsed/refractory AML patients. The abstract describes full clinical data from four patients in Cohort 1 and references the enrollment of the first two patients in Cohort 2 as of the August 2nd abstract submission date. The clinical data from the four patients in Cohort 1 showed evidence that MGTA-117 (i) binds to cells expressing CD117 target, (ii) depletes target cells and (iii) clears the body rapidly with no detectable free payload. In addition, and as previously referenced, one Cohort 1 patient achieved complete remission after receiving MGTA-117 and proceeded to a conditioning regimen followed by stem cell transplant. As described in the abstract, MGTA-117 was well-tolerated with no serious adverse events deemed related to MGTA-117 and no dose-limiting toxicities. As described separately, in addition to the results described in the published abstract, Magenta will present updated available clinical data.

Poster presentation characterizing MGTA-117 Pharmacokinetic (PK) and Pharmacodynamic (PD) in Non-Human Primates (NHPs)
Title: The Pharmacokinetic and Pharmacodynamic Characterization of MGTA-117, an Anti-CD117-Amanitin Antibody-Drug Conjugate for Targeted Conditioning Prior to Transplant, in Non-Human Primates
Date: Monday, December 12, 2022, 6:00-8:00 pm CT
Abstract Summary: MGTA-117 was designed to deplete target cells via a dual-mechanism: direct cell killing from the ADC payload plus blocking of stem cell factor binding by the antibody. Stem cell factor naturally binds to CD117 and is needed for cell survival and proliferation. MGTA-117 was administered across a range of doses in primates to assess the time course of PK, PD and depletion of stem cells. At multiple dose levels, MGTA-117 showed greater than 90% depletion of stem cells in the bone marrow. All dose levels showed rapid rates of MGTA-117 clearance that, together with evidence showing robust stem cell depletion, supports the potential use of MGTA-117 to deplete target cells prior to a patient’s hematopoietic stem cell transplant or infusion of any ex vivo gene therapy product. To date, the PK and PD data and modeled projections derived from this NHP study have been predictive of MGTA-117’s clinical experience.

MGTA-145 Stem Cell Mobilization and Collection
Magenta is developing MGTA-145, in combination with plerixafor, to improve the process by which stem cells are stimulated out of the bone marrow and into the bloodstream, known as stem cell mobilization. The mobilized cells are then collected and available for transplant. This is the first step for patients and is required for the majority of transplants and stem cell gene therapies.

Poster presentation of the ongoing Phase 2 clinical study in sickle cell disease
Title: A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of MGTA-145 in Combination with Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients with Sickle Cell Anemia
Date: Monday, December 12, 2022, 6:00-8:00 pm CT
Abstract Summary: This is a Phase 2 open-label clinical trial designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of one or two doses of MGTA-145 combined with plerixafor for the mobilization of hematopoietic stem cells in patients with sickle cell disease. The primary endpoint is the total number of collected stem cells. Key exploratory endpoints include characterization of the phenotype and function of cells collected by apheresis and assessment of the potential for collected cells to undergo gene modification. The results of this clinical trial will provide direction regarding the potential of MGTA-145, in combination with plerixafor, to rapidly and safely mobilize sufficient numbers of high-quality stem cells for hematopoietic stem cell transplant in patients with sickle cell disease.

Magenta Research Platform
Magenta’s research platform is focused on discovering, engineering and advancing novel molecules, including ADCs, that target specific cells for depletion in patients receiving stem cell transplants and cell and gene therapies. Targeted depletion is intended to improve the efficacy and safety of stem cell transplant and cellular therapies by replacing or reducing the use of chemotherapy.

Oral presentation of Magenta Research ADC in a NHP transplant model (Academic Collaborator)
Title: Targeted Deletion of Activated T Cells with a Single Dose of Anti-CD137-Antibody Drug Conjugate Protects Against Acute GVHD (AGVHD) and Promotes Tolerogenic T Cell Reconstitution after Haplo-Identical Hematopoietic Stem Cell Transplantation (HSCT)
Date: Sunday, December 11, 2022, 4:30 pm CT
Abstract Summary: This collaborative preclinical study compared the outcomes of an allogeneic transplant in NHPs treated with either no graft-versus-host-disease (GVHD) prophylaxis (NoRx) or a single dose of an ADC targeting CD137 post-transplant (CD137-ADC). CD137 (4-1BB) is a cell surface target that is rapidly upregulated on activated T-cells following transplant, making this a promising drug target to prevent GVHD before it is initiated. All NHP transplant recipients receiving the ADC engrafted with donor cells demonstrating > 90% chimerism. NHPs treated with a single dose of CD137-ADC had a median survival of 97 days, which was significantly longer than the 8 days median survival in the control NoRx group. There were no treatment-related toxicities. This preclinical proof-of-concept for a CD137-based, single-dose, targeted therapy to prevent acute GVHD shows the potential of ADC-based targeted cell depletion to improve the efficacy and safety of allogeneic stem cell transplant and cell therapies.

Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting

On November 3, 2022 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, reported that it will present initial data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 clinical trial at the 64th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, taking place December 10-13, 2022 in New Orleans, LA (Press release, Syros Pharmaceuticals, NOV 3, 2022, View Source [SID1234622918]). The SELECT-AML-1 trial is evaluating tamibarotene, Syros’ first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine in patients with newly diagnosed, unfit acute myeloid leukemia (AML) with RARA gene overexpression.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation are as follows:

Presentation Title: Initial Results from SELECT-AML-1, a Phase 2 study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy
Session Title: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Session Date & Time: Saturday, December 10, 2022, 5:30 – 7:30 pm CT (6:30 – 8:30 pm ET)
Location: Ernest N. Morial Convention Center, Hall D
Publication Number: 1444

The abstract is now available online on the ASH (Free ASH Whitepaper) Conference website at:
View Source

Geron Announces Presentations at Upcoming ASH Annual Meeting Including Long-term Phase 2 Data Showing Continuous Durable Transfusion Independence in Patients with Lower Risk MDS

On November 3, 2022 Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, reported that four abstracts related to imetelstat, a first-in-class telomerase inhibitor, have been accepted for presentation at the 64th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting taking place from December 10-13 in New Orleans, Louisiana (Press release, Geron, NOV 3, 2022, View Source [SID1234622917]). A fifth abstract has been published on the ASH (Free ASH Whitepaper) website and will be available in Blood. These abstracts assess the potential of imetelstat in various blood cancers, or hematologic malignancies, including lower risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), myelofibrosis (MF) and lymphoid malignancies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The upcoming presentation at ASH (Free ASH Whitepaper) of the longer-term follow-up data from our Phase 2 IMerge trial showing unprecedented greater than one-year continuous transfusion independence in approximately one-third of the 38 lower risk MDS patients in the study highlights the differentiating qualities of imetelstat that could address significant unmet needs in this indication," said Faye Feller, M.D., Executive Vice President, Chief Medical Officer of Geron. "We look forward to reporting top-line results from the Phase 3 IMerge trial shortly after ASH (Free ASH Whitepaper), in early January 2023."

Dr. Feller continued: "Further, I am pleased to see other abstracts representing our imetelstat pipeline at ASH (Free ASH Whitepaper), demonstrating broad potential for the drug in hematologic malignancies."

Clinical Data – Lower Risk Myelodysplastic Syndromes (MDS)

Abstract #459: "Imetelstat Achieved Prolonged, Continuous Transfusion Independence in Patients With Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory to Erythropoiesis Stimulating Agents Within the IMerge Phase 2 Study"

Oral Presentation on December 11, 2022, at 5pm CT

The abstract describes the 29% (11/38) of patients in Phase 2 IMerge who achieved a greater than one-year sustained transfusion independence (TI). These transfusion dependent patients were treated with imetelstat for a median of 126.1 weeks (range: 70.1-168.1), and their median duration of TI was 92.4 weeks (95% CI: 69.6, 92.4). After a median follow-up of 51.5 months, median progression-free survival (PFS) was 34.2 months (95% CI: 25.1, 39.2), median overall survival (OS) was 57.0 months (95% CI: 29.4, NE), and none of these patients progressed to AML.

Mutation data was available for the majority of the patients who achieved greater than 1-year sustained TI, and 89% had any reduction in SF3B1 variant allele frequency (VAF) while 56% achieved greater than or equal to 50% VAF reduction. Reduction in VAF correlated with longer TI duration and shorter time to onset of TI.

Safety findings for these patients were consistent with the overall population, and the most frequent adverse events were reversible thrombocytopenia and neutropenia.

The abstract concludes that the greater than one-year periods of transfusion independence observed in these patients represents relief from iron overload and other transfusion associated complications, and decreased demand on healthcare resources. Furthermore, durable TI, meaningful reduction in mutational burden, and good survival post-ESA suggest imetelstat may have disease-modifying activity.

Non-Clinical Data – Acute Myeloid Leukemia

Abstract #201: "Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia"

Oral Presentation on December 10, 2022, at 2:30pm CT

This abstract describes results from non-clinical in vitro and animal in vivo experiments of imetelstat using AML cell lines and AML patient samples. Conducted by Geron collaborators in Australia, Germany and the U.S., the experiments found that imetelstat promotes the formation of polyunsaturated fatty acids-containing phospholipids which cause excessive levels of lipid peroxidation and oxidative stress in AML cells, potentially leading to programmed cell death. The abstract concludes that this mechanistic insight could be leveraged to develop an optimized therapeutic strategy using oxidative stress-inducing chemotherapy to sensitize patient samples to imetelstat causing significant delay of relapse in AML.

Trials in Progress Poster Presentations – Myelofibrosis

Abstract #3037: "MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor"

Poster Presentation on December 11, 2022, 6-8pm CT

MYF3001, or IMpactMF (NCT04576156), is a Phase 3, randomized (2:1), open label multicenter study of imetelstat compared with best available therapy (BAT) in approximately 320 adult patients with Intermediate-2 or High-Risk MF whose disease has relapsed after or is refractory to janus associated kinase inhibitor, or JAKi, treatment. The primary endpoint is overall survival and secondary endpoints include symptom and spleen response rates at Week 24, progression-free survival, clinical response assessments, time to and duration of response, reduction in degree of bone marrow fibrosis, safety, pharmacokinetics and patient-reported outcomes. Biomarkers and mutation analyses will be performed to evaluate the impact of imetelstat on reduction/depletion of malignant clones. Approximately 180 sites are planned in North and South America, Europe, Middle East, Australia and Asia. The study is actively enrolling.

Abstract #1713: "An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate-1, Intermediate-2 or High-Risk Myelofibrosis"

Poster Presentation on December 10, 5:30-7:30pm CT

MYF1001, or IMproveMF (NCT05371964), is a single arm, open label, two-part Phase 1 study to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of imetelstat in combination with ruxolitinib as a frontline treatment in patients with Intermediate-1 or -2 or High-risk MF (frontline MF). In both parts, patients will receive ruxolitinib followed by imetelstat. Part 1 will enroll up to 20 frontline MF patients who, at the time of enrollment, have received an optimized dose of ruxolitinib, to which imetelstat treatment will be added at increasing dose levels based on safety and tolerability. The primary purpose of Part 1 is to identify a safe dose for treating frontline MF patients with a combination of imetelstat and ruxolitinib. If a safe dose is identified in Part 1, participants in Part 2 will be JAK inhibitor naïve and will receive treatment with ruxolitinib after screening and enrollment at a starting dose based on standard-of-care or local prescribing information. Treatment with single-agent ruxolitinib will continue for at least 12 weeks, including four consecutive weeks at a stable dose prior to the addition of imetelstat. Part 2 is designed to confirm the safety profile of imetelstat in combination with ruxolitinib and to evaluate for preliminary clinical activity of the combination. Part 1 is open for enrollment, with approximately three sites planned in North America.

Non-Clinical Data – Lymphoid Malignancies

Published online in Blood: "Pharmacological Inhibitory Effect of Imetelstat, A Novel Human Telomerase Inhibitor in Diffuse Large B-cell Lymphoma and Peripheral T-Cell Lymphoma"

This abstract describes the characterization of telomerase activity and telomere length, as well as results from in vitro experiments of imetelstat, on a panel of diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphomas (PTCL) cell lines. This work was conducted by Geron collaborators at MD Anderson Cancer Center. These in vitro experiments found that imetelstat reduced cell viability and increased apoptosis in DLBCL cell lines. In contrast, imetelstat single-agent activity on cell viability was limited in PTCL cell lines, even though a time and dose-dependent reduction of telomerase activity were noted. The greater inhibitory effect of imetelstat in DLBCL, compared to PTCL cell lines, may be attributed to higher telomerase activity observed in DLBCL compared to PTCL cells. Furthermore, the PTCL cell lines had a ~7.3 fold longer telomere length than DLBCL cell lines, which potentially also influenced the lower response to imetelstat.

The abstracts are available on the ASH (Free ASH Whitepaper) website at www.hematology.org.

In accordance with ASH (Free ASH Whitepaper) policies, abstracts submitted to the ASH (Free ASH Whitepaper) Annual Meeting are embargoed from the time of submission. To be eligible for presentation at the ASH (Free ASH Whitepaper) Annual Meeting, any additional data or information to be presented at the Annual Meeting may not be made public before the presentation. The presentations and posters will be available at www.geron.com/r-d/publications following the ASH (Free ASH Whitepaper) Annual Meeting presentations.

About Imetelstat

Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in hematologic malignancies. Data from Phase 2 clinical trials provide strong evidence that imetelstat targets telomerase to inhibit the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies resulting in malignant cell apoptosis and potential disease-modifying activity. Imetelstat has been granted Fast Track designation by the United States Food and Drug Administration for both the treatment of patients with non-del(5q) lower risk MDS who are refractory or resistant to an erythropoiesis stimulating agent and for patients with Intermediate-2 or High-risk MF whose disease has relapsed after or is refractory to janus associated kinase (JAK) inhibitor treatment.

ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting

On November 3, 2022 ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, reported the Company will be presenting clinical data from the dose escalation portion of ASPEN-05, a Phase 1 study evaluating evorpacept in combination with azacitidine and venetoclax for the treatment of acute myeloid leukemia ("AML") at the 64th American Society of Hematology (ASH) (Free ASH Whitepaper) ("ASH") Annual Meeting held December 10-13, 2022 in New Orleans, Louisiana (Press release, ALX Oncology, NOV 3, 2022, View Source [SID1234622916]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The accepted abstract is listed below and is now available online on the ASH (Free ASH Whitepaper) website: View Source

Poster Presentation Details

Title: Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part

Session Name: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III

Presentation Date and Location: Monday, December 12, 2022, 6:00pm – 8:00pm CT, Ernest N. Morial Convention Center, Hall D

Publication Number: 4076